JB/CALL/MODERNA/130/0.0333/20.06.25 | Real-time Bid/Ask 10:02:40 2024-07-11 am EDT | ||
| 0.82 CHF / 0.83 CHF | +13.01% |
|
| Current month | -5.19% | ||
| 1 month | -44.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-10 | 0.73 | +1.39% |
| 24-07-04 | 0.72 | +2.86% |
| 24-07-02 | 0.7 | -5.41% |
Delayed Quote Swiss Exchange
Last update July 10, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Bank Julius Bär |
| MRNPJB | |
| ISIN | CH1317202161 |
| Date issued | 2024-01-18 |
| Strike | 130 $ |
| Maturity | 2025-06-20 (344 Days) |
| Parity | 30 : 1 |
| Emission price | 0.59 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.83 CHF |
|---|---|
| Lowest since issue | 0.35 CHF |
| Spread | 0.01 CHF |
| Spread % | 1.20% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
117.4
USD
Average target price
145.9
USD
Spread / Average Target
+24.19%
- Stock Market
- Warrants
- MRNPJB Warrant
